The LATAM Generic Drug Playbook: Patent Cliffs, Regulatory Arbitrage, and Why Most Multinationals Get It Wrong The Latin American generic […]

Part 1: The Economics of Biopharma Risk: Why Standard Research Isn’t Enough The cost to bring a new molecular entity

Introduction: The Patent Cliff Is Yesterday’s Problem The pharmaceutical industry spent decades obsessing over the patent cliff, that moment when

How to quantify pharmaceutical patent assets, structure patent-backed financing, and convert exclusivity data into investment-grade capital strategies 1. Why Pharma

Formulary management is a nine-figure business problem dressed up as a clinical workflow. Every Pharmacy & Therapeutics (P&T) committee in

Part I: The Strategic Imperative – Patent Risk as a Financial Variable {#part-i} The $2.6 Billion Problem No Pipeline Model

1. The Patent Bargain, Recalibrated: What the Ruling Actually Did On May 18, 2023, the U.S. Supreme Court issued a

Why IP Benchmarking Is a Revenue Function, Not a Legal One A composition of matter patent on a new drug

Section 1: The Broken Bargain: How a 20-Year Monopoly Became a 40-Year Rent The patent system’s foundational premise is blunt: